Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Stefano Landi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8364-6357; OpenAlex author ID A5040591887. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 6 papers · 2024: 1 paper · 2025: 2 papers

Papers 32

  1. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  2. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. Co-author DOI 10.1016/j.semcancer.2025.05.004↗
  3. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  4. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  5. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  6. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  7. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  8. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  9. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  10. Germline genetic variability in pancreatic cancer risk and prognosis. Co-author DOI 10.1016/j.semcancer.2020.08.003↗
  11. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  12. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  13. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  14. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  15. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  16. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  17. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  18. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  19. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  20. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  21. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  22. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  23. Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Co-author DOI 10.1158/1055-9965.epi-17-0075↗
  24. Environmental risk factors for pancreatic cancer: an update. Last author DOI 10.1007/s00204-016-1821-9↗
  25. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  26. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  27. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  28. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  29. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  30. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  31. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  32. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniele Campa · 9 shared papers, 2013–2025 · strength 0.71
  2. Federico Canzian · 8 shared papers, 2013–2023 · strength 0.51
  3. Pavel Vodička · 6 shared papers, 2013–2025 · strength 0.43
  4. Lívia Archibugi · 3 shared papers, 2018–2025 · strength 0.37
  5. Gabriele Capurso · 7 shared papers, 2013–2023 · strength 0.33
  6. Ľudmila Vodičková · 5 shared papers, 2013–2025 · strength 0.32
  7. Cosmeri Rizzato · 5 shared papers, 2013–2025 · strength 0.32
  8. Riccardo Farinella · 2 shared papers, 2023–2025 · strength 0.31
  9. Manuel Gentiluomo · 2 shared papers, 2022–2023 · strength 0.30
  10. John P. Neoptolemos · 6 shared papers, 2013–2023 · strength 0.28
  11. Francesca Tavano · 5 shared papers, 2013–2023 · strength 0.28
  12. Thilo Hackert · 4 shared papers, 2017–2023 · strength 0.25
  13. Rita Teresa Lawlor · 4 shared papers, 2017–2023 · strength 0.25
  14. David J. Hughes · 2 shared papers, 2017–2025 · strength 0.24
  15. Daniela Basso · 4 shared papers, 2013–2023 · strength 0.23
  16. Pavel Souček · 5 shared papers, 2013–2023 · strength 0.23
  17. Raffaele Pezzilli · 5 shared papers, 2013–2023 · strength 0.23
  18. Renata Talar‐Wojnarowska · 6 shared papers, 2013–2018 · strength 0.22
  19. Beatrice Mohelníková-Duchoňová · 4 shared papers, 2013–2023 · strength 0.20
  20. Neil Daniel · 1 shared paper, 2025 · strength 0.20
  21. Annalisa Comandatore · 1 shared paper, 2025 · strength 0.20
  22. Ruggero Ponz de Leon Pisani · 1 shared paper, 2025 · strength 0.20
  23. Giulia Peduzzi · 1 shared paper, 2025 · strength 0.20
  24. Pinar Uysal Onganer · 1 shared paper, 2025 · strength 0.20
  25. Juan Sáinz · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.